Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

随着经济高速发展和工业化进程的加速, 生活方式的改变和老龄化进程的加速,
使我国糖尿病的患病率正呈快速上升的趋势, 成为继心脑血管疾病, 肿瘤之后另一个严重危害 …

Introduction In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a
priority list, endorsed by the World Health Organization, of potential adverse events relevant …

The term ferroptosis coined in 2012 causes acute kidney injury (AKI). However, its pathway
mechanism in AKI is poorly understood. In this study, we conducted an RNA-sequence …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Heart failure (HF) has been recognized as a common complication of diabetes, with a
prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …